Gayet Maudy C W, van der Aa Anouk A M A, Beerlage Harrie P, Schrier Bart Ph, Gielens Maaike, Heesakkers Roel, Jager Gerrit J, Mulders Peter F A, Wijkstra Hessel
Department of Urology, Jeroen Bosch Hospital, Henri Dunantstraat 1, 5223 GZ, 's-Hertogenbosch, Netherlands.
Department of Electrical Engineering, Eindhoven University of Technology, De Rondom 70, 5612 AP, Eindhoven, Netherlands.
Prostate Cancer. 2020 Apr 3;2020:4626781. doi: 10.1155/2020/4626781. eCollection 2020.
To compare prostate cancer detection rates (CDRs) and pathology results with targeted prostate biopsy (TB) and systematic prostate biopsy (SB) in biopsy-naive men.
An in-patient control study of 82 men undergoing SB and subsequent TB in case of positive prostate MRI between 2015 and 2017 in the Jeroen Bosch Hospital, the Netherlands.
Prostate cancer (PCa) was detected in 54.9% with 70.7% agreement between TB and SB. Significant PCa (Gleason score ≥7) was detected in 24.4%. The CDR with TB and SB was 35.4% and 48.8%, respectively (=0.052). The CDR of significant prostate cancer with TB and SB was both 20.7%. Clinically significant pathology upgrading occurred in 7.3% by adding TB to SB and 22.0% by adding SB to TB.
There is no statistically significant difference between CDRs of SB and TB. Both SB and TB miss significant PCas. Moreover, pathology upgrading occurred more often by adding SB to TB than vice versa. This indicates that the omission of SB in this study population might not be justified.
比较初次活检男性中靶向前列腺活检（TB）和系统前列腺活检（SB）的前列腺癌检出率（CDR）及病理结果。
在荷兰杰罗恩·博世医院进行的一项住院对照研究，纳入了2015年至2017年间接受SB且在前列腺MRI呈阳性时接受后续TB的82名男性。
54.9%的患者检测出前列腺癌（PCa），TB与SB的一致性为70.7%。24.4%的患者检测出显著前列腺癌（Gleason评分≥7）。TB和SB的CDR分别为35.4%和48.8%（P = 0.052）。TB和SB检测显著前列腺癌的CDR均为20.7%。在SB基础上加做TB时，临床显著病理升级发生率为7.3%；在TB基础上加做SB时，临床显著病理升级发生率为22.0%。
SB和TB的CDR之间无统计学显著差异。SB和TB都会漏诊显著PCa。此外，在TB基础上加做SB时病理升级更常见，反之则不然。这表明在该研究人群中省略SB可能不合理。
